How Ozempic and GLP-1 drugs affect blood pressure
Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes, while the higher-dose version, Wegovy, is approved for weight loss. Both medications have been shown to lower blood pressure in large clinical trials, and in 2026, we have more evidence than ever about how significant this effect is.
The most important trial is SELECT, published in the New England Journal of Medicine and updated with final results in March 2026. It studied semaglutide 2.4 mg (Wegovy) in over 17,000 people with obesity and existing cardiovascular disease but without diabetes. This trial proved that GLP-1 drugs benefit the heart and blood pressure even when blood sugar is not the issue.
| Trial | Drug/Dose | Systolic BP Reduction | Diastolic BP Reduction | Population |
|---|---|---|---|---|
| SELECT (2026) | Semaglutide 2.4 mg | -4.2 mmHg | -2.5 mmHg (est.) | Obesity + CVD, no diabetes |
| STEP Trials (pooled) | Semaglutide 2.4 mg | -3.6 to -5.1 mmHg | -1.7 to -2.8 mmHg | Obesity, no diabetes |
| SUSTAIN-6 | Semaglutide 0.5-1 mg | -3.3 mmHg | No significant change | Type 2 diabetes |
| SURMOUNT-1 | Tirzepatide 10-15 mg | -6.2 mmHg | -4.0 mmHg | Obesity, no diabetes |
| SOUL (2026) | Oral semaglutide 14 mg | -3.5 mmHg (estimated) | Not reported | Type 2 diabetes + CVD |
Across all these trials, the pattern is clear: GLP-1 drugs lower systolic blood pressure by 3-5 mmHg, with tirzepatide showing even larger reductions (6+ mmHg). These numbers might sound small, but at a population level, a 3-5 mmHg reduction translates into a 7-10% reduction in stroke risk and 5-7% reduction in heart attack risk.
Is the blood pressure effect just from weight loss?
Partly, but not entirely. Weight loss does lower blood pressure. For every kilogram (2.2 pounds) lost, systolic blood pressure drops by approximately 1 mmHg. Given that people on semaglutide 2.4 mg lose 10-15% of their body weight on average (12-18 kg for someone starting at 120 kg), you would expect a 12-18 mmHg drop just from weight loss.
But the observed reductions are only 3-5 mmHg. What gives? The answer is that observed blood pressure changes in trials reflect the real-world experience, where not everyone loses maximum weight, some people regain weight, and blood pressure responds variably. More importantly, studies have found that GLP-1 drugs lower blood pressure even in people who do not lose much weight, suggesting weight-independent mechanisms.
Mechanisms beyond weight loss
- Natriuresis: GLP-1 receptor activation in the kidneys increases sodium excretion, reducing blood volume and pressure. This effect occurs independently of weight changes.
- Endothelial function: GLP-1 improves the function of the cells lining blood vessels, increasing nitric oxide production. Nitric oxide is a vasodilator, meaning it relaxes blood vessels and lowers pressure.
- Sympathetic nervous system modulation: GLP-1 may reduce overactivity of the fight-or-flight nervous system, which is often elevated in obesity and hypertension.
- Anti-inflammatory effects: Chronic low-grade inflammation contributes to hypertension. GLP-1 drugs reduce inflammatory markers like C-reactive protein and interleukin-6, which may improve vascular health.
- Improved insulin sensitivity: Insulin resistance is linked to high blood pressure through several pathways. GLP-1 drugs improve insulin sensitivity, which may indirectly lower blood pressure.
A 2024 individual patient data meta-analysis published in Atherosclerosis found that blood pressure reductions with semaglutide were similar in people with and without hypertension at baseline. This suggests the effect is not just about correcting existing high blood pressure, but about improving overall cardiovascular function.
Cardiovascular outcomes: more than just blood pressure
The SELECT trial found a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide, including heart attacks, strokes, and cardiovascular death. This is a massive result. But interestingly, blood pressure reduction alone does not fully explain this benefit.
Participants in SELECT also experienced:
- 18% reduction in triglycerides
- 12% reduction in lipoprotein(a), a cholesterol particle linked to heart disease
- Reduction in inflammatory markers
- Improved glycemic control, even in people without diabetes
Dr. A. Michael Lincoff, the trial's principal investigator, noted that while blood pressure reduction is clinically meaningful, the cardiovascular benefit of semaglutide likely comes from multiple mechanisms working together. This makes GLP-1 drugs uniquely powerful for people with obesity and cardiovascular risk.
Wegovy vs Ozempic vs Mounjaro: blood pressure comparison
Ozempic and Wegovy are both semaglutide, a GLP-1 receptor agonist. The difference is dosing: Ozempic is approved for diabetes at 0.5 mg, 1 mg, or 2 mg weekly, while Wegovy is approved for weight loss at up to 2.4 mg weekly. Wegovy's higher dose produces greater weight loss and, consequently, greater blood pressure reduction.
Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for weight loss) are different. Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, giving it a dual mechanism. In head-to-head trials, tirzepatide produces more weight loss and larger blood pressure reductions than semaglutide.
| Medication | Active Ingredient | Max Dose | Avg Weight Loss | Systolic BP Reduction |
|---|---|---|---|---|
| Ozempic | Semaglutide (GLP-1) | 2 mg weekly | 6-8% | -3 to -4 mmHg |
| Wegovy | Semaglutide (GLP-1) | 2.4 mg weekly | 10-15% | -4 to -5 mmHg |
| Mounjaro | Tirzepatide (GLP-1/GIP) | 15 mg weekly | 12-16% | -5 to -6 mmHg |
| Zepbound | Tirzepatide (GLP-1/GIP) | 15 mg weekly | 15-21% | -6 to -7 mmHg |
The SURMOUNT-5 trial, a head-to-head comparison published in 2025, showed that tirzepatide users experienced greater systolic blood pressure reduction compared to semaglutide users, alongside an average of 6.5% more weight loss (20.2% vs 13.7%).
What happens to blood pressure when you stop Ozempic
The cardiovascular benefits of GLP-1 drugs, including blood pressure reduction, depend on continued treatment. Studies of people who stopped semaglutide or tirzepatide show that weight is gradually regained, and blood pressure returns toward pre-treatment levels over months.
There is no evidence of rebound hypertension, where blood pressure spikes above baseline after stopping. The return to baseline is gradual and parallels weight regain. This is similar to what happens when people stop other weight-loss interventions, whether medication, surgery, or diet.
Long-term treatment
Can you take Ozempic with high blood pressure medication?
Yes. People with hypertension can and do take GLP-1 medications safely. In fact, many clinical trial participants were on blood pressure medications at baseline, and the blood pressure benefits were similar whether or not people were already treated.
However, as you lose weight and blood pressure drops, your existing blood pressure medication may become too strong, leading to hypotension (too-low blood pressure). Symptoms of hypotension include:
- Dizziness or lightheadedness, especially when standing
- Fatigue or weakness
- Fainting or near-fainting episodes
- Nausea
- Blurred vision
If you experience these symptoms after starting Ozempic or Wegovy, contact your doctor. They may reduce the dose of your blood pressure medication or discontinue one drug if you are on multiple. Never stop blood pressure medication on your own.
Track your blood pressure at home
Who should consider GLP-1 drugs for cardiovascular benefits
The American College of Cardiology now includes GLP-1 receptor agonists in cardiovascular disease prevention guidelines for people with obesity. Based on SELECT and other trials, the strongest evidence supports use in:
- People with BMI 27+ and existing cardiovascular disease (prior heart attack, stroke, or coronary artery disease)
- People with obesity (BMI 30+) and additional cardiovascular risk factors like hypertension, high cholesterol, or prediabetes
- People with type 2 diabetes and high cardiovascular risk
GLP-1 drugs are not approved solely for treating high blood pressure, and they are not a substitute for proven blood pressure medications. But for people who meet criteria for weight loss or diabetes treatment, the blood pressure and cardiovascular benefits are significant added value.
The bottom line
Ozempic and Wegovy (semaglutide) lower systolic blood pressure by 3-5 mmHg on average, with tirzepatide showing even greater reductions (6+ mmHg). This effect is partly independent of weight loss and comes from multiple mechanisms including improved kidney sodium handling, better blood vessel function, and reduced inflammation.
The blood pressure benefit adds to the broader cardiovascular protection seen in major trials like SELECT, which showed a 20% reduction in heart attacks, strokes, and cardiovascular death. These medications are not blood pressure drugs, but for people with obesity and cardiovascular risk, they offer meaningful blood pressure and heart health benefits alongside weight loss.
